Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer.

PET radiotracers have become indispensable in the care of patients with breast cancer.  ¹⁸ F-fluorodeoxyglucose has become the preferred method of many oncologists for systemic staging of breast cancer at initial diagnosis, detecting recurrent disease, and for measuring treatment response after therapy.  ¹⁸ F-Sodium Fluoride is valuable for detection of osseous metastases.  ¹⁸ F-fluoroestradiol is now FDA-approved with multiple appropriate clinical uses. There are multiple PET radiotracers in clinical trials, which may add utility of PET imaging for patients with breast cancer in the future. This article will describe the advances during the last quarter century in PET for patients with breast cancer.
Competing Interests: Disclosure G.A. Ulaner discloses grants, consulting fees, honoraria, and/or speaker fees from Curium, GE Heathcare, Lantheus, Nuclidium, POINT, RayzeBio, Briacell, and ImaginAb. S.C. Vaz has no disclosures to declare. D. Groheux has no disclosures to declare.
(Copyright © 2023 Elsevier Inc. All rights reserved.)